Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study.

[1]  P. Campochiaro,et al.  Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes—Protocol 3 with high dose) , 2015, Eye.

[2]  Allen C Ho,et al.  Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. , 2013, Ophthalmology.

[3]  Judy E. Kim,et al.  Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. , 2012, Archives of ophthalmology.

[4]  Quan Dong Nguyen,et al.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. , 2012, Ophthalmology.

[5]  Thomas W. Gardner,et al.  The restore study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema , 2011 .

[6]  Elham Hatef,et al.  Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. , 2010, Ophthalmology.

[7]  Lloyd Paul Aiello,et al.  Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema , 2010, Ophthalmology.

[8]  Jennifer I. Lim,et al.  Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. , 2009, Ophthalmology.

[9]  P. Campochiaro,et al.  Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. , 2006, American journal of ophthalmology.

[10]  Allen C Ho,et al.  Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. , 2014, Ophthalmology.